Adicet Bio Inc To Provide Update On Clinical Pipeline And Corporate Outlook Call Transcript
Good morning and thank you all for joining us today. I'm Chen Schor, President, CEO of Adicet Bio. By now, you've seen the press release we issued this morning announcing important updates for our lead asset, ADI-001. We're excited to share a corporate update today that we believe has the potential to unlock significant value for both patients and shareholders. Let's get right to it.
As a reminder, we'll be making forward-looking statements today as detailed on the slide, including express or implied statements regarding ADI-001, our future plans and strategy, and other statements that are not historical facts. Please also refer to the forward-looking statement from today's press release as well as the risk factors section in our most recent 10-K and subsequent SEC filings for more details. This call is being recorded.
On the call with me today are Dr. Francesco Galimi, Chief Medical Officer; Dr. Blake Aftab, Chief Scientific Officer; and Nick Harvey, Chief Financial Officer. We're excited to kick off 2024 with a goal of unlocking the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
